
HTG Molecular Diagnostics HTGM
Annual report 2022
added 03-30-2023
HTG Molecular Diagnostics Accounts Payables 2011-2026 | HTGM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 M | 1.65 M | 1.35 M | 1.66 M | 1.85 M | 2.44 M | 762 K | 725 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | 725 K | 1.45 M |
Quarterly Accounts Payables HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 710 K | 1.12 M | 1.32 M | 1.65 M | 1.15 M | 1.68 M | 1.35 M | 1.35 M | 1.35 M | 1.35 M | 1.35 M | 1.66 M | 1.66 M | 1.66 M | 1.66 M | 1.85 M | 1.85 M | 1.85 M | 1.85 M | 2.44 M | 2.44 M | 2.44 M | 2.44 M | 762 K | 762 K | 762 K | 762 K | 725 K | 725 K | 725 K | 725 K | 948 K | 948 K | 948 K | 948 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | 710 K | 1.37 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
10.9 M | $ 8.62 | 0.23 % | $ 574 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
DexCom
DXCM
|
344 M | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
176 M | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 14.77 | 0.61 % | $ 447 M | ||
|
Guardant Health
GH
|
54.4 M | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
165 K | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Danaher Corporation
DHR
|
1.84 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
221 M | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
446 M | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 9.0 | -0.99 % | $ 255 M | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 450.41 | 1.48 % | $ 13 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
Celcuity
CELC
|
9.37 M | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
OPKO Health
OPK
|
47.1 M | $ 1.19 | 2.59 % | $ 826 M | ||
|
Natera
NTRA
|
31.1 M | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 4.66 | -3.92 % | $ 432 M | ||
|
Pacific Biosciences of California
PACB
|
20.8 M | $ 1.33 | 4.72 % | $ 399 M |